WiCON | Pharma China (Web Edition)

ONLINE ENQUIRY

WiCON International Group
Bellevue, WA 98007, USA
info@pharmachinaonline.com

WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com

High Return Rate: Are Chinese Innovative Drugs Facing a "Breakup" Crisis in Ov... Analysis of Booming License-Out Deals Reveals a Concerning Trend of Terminated Collaborations for Chinese Pharmaceutical Companies, according to a recent feature article ...
(4/29/2025)

China Still Go-To Source for New Drugs Despite... (5/9/2025)

Redefining Translational Research and China's ... (5/8/2025)

China Introduces A New Regulatory Data Protect... (5/5/2025)

Pharma's Crossroads: U.S. Investment Surges Un... (5/1/2025)

High Return Rate: Are Chinese Innovative Drugs... (4/29/2025)

China Aims for Significant Pharma Industry Dig... (4/26/2025)

MNC Pharma's Q1/2025 China Performance: Diverg... (4/25/2025)

Cell Therapy to AI: How J&J Has Been Sourcing ... (4/25/2025)

China Biopharma Tracker – March 2025 (PharmaD... (4/24/2025)

US Capital Crunch Pushes China Biotechs to Rou... (4/24/2025)

Cheaper Chinese HPV Vaccines Turn Merck's Gard... (4/23/2025)

China Broadens Healthcare Access: Foreign Doct... (4/22/2025)

Chinese Biotechs Turn to Switzerland as ... (5/9/2025) China Grants Tariff Exemptions on Select... (5/9/2025) 83 Listed Chinese Pharma Firms Top 70% M... (5/9/2025) Dementia Cases Surge in China at an Unpr... (5/8/2025) CDE Seeks Comments on Draft Guidelines f... (5/7/2025) CDE Publicizes the List of Reference For... (5/7/2025) Roche's Columvi Wins Expanded Approval i... (5/7/2025) Novo Nordisk Sees Surge in China on Wego... (5/7/2025) Everest Medicines Announces NMPA Full Ap... (5/7/2025) Early Clinical Data from China Show Prom... (5/7/2025) AccurEdit's In Vivo Gene-Editing Drug AR... (5/7/2025) Innovent Presents Positive Phase 2 Data ... (5/7/2025) Immunochina’s IM96 CAR-T Cell Therapy W... (5/6/2025) China Approves Six Novel Drugs in April ... (5/6/2025) Kintor Reports Superior Hair Regrowth Re... (5/6/2025) CStone Unveils Promising Preclinical Dat... (5/6/2025) China Seeks Public Feedback on Draft Gui... (5/6/2025) China Seeks Public Feedback on ICH Q1 St... (5/6/2025)

China's Hospital Drug Market Shows Slight Growth in 202... China Unveils Ambitious Plan to Boost Health-Related Co... Chinese VMS OTC Market Growth Slowed to 2.7% in 2024 Newish Tech Secures Series B Financing to Advance Next-... China's Retail Pharmacy Market Reaches CNY 574 Billion ...

83 Listed Chinese Pharma Firms Top 70% Margins in 2024 China Grants Tariff Exemptions on Select Pharmaceutical... Chinese Biotechs Turn to Switzerland as U.S. Partnershi... Innovent Presents Positive Phase 2 Data for First-in-Cl... AccurEdit's In Vivo Gene-Editing Drug ART001 Shows Sust...

CDE Publicizes the List of Reference Formulations for G... CDE Seeks Comments on Draft Guidelines for Subject Sele... China Announces Ambitious Plan to Optimize Primary Heal... China Seeks Public Feedback on ICH Q1 Stability Testing... China Seeks Public Feedback on Draft Guideline for Risk...

Dementia Cases Surge in China at an Unprecedented Rate NHC Ministers Meet with Top Pharma MNC Executives Beijing Unveils Ambitious Policy Package to Supercharge... China's BMI Fund Surpasses CNY16.5 Trillion with 11% An... Growing Awareness and Expanding Treatment Options for S...

AstraZeneca Faces Escalating Legal Challenges in China ... BeiGene Secures Key Patent Victory in Brukinsa Dispute ... State Council Approves Draft Medical Security Law, Stre... Novo Nordisk Sues KBP Biosciences for $830 Million Over... State Council Releases Final Antitrust Guidelines for t...

FDA Issues Warning Letters to Two Chinese API Manufactu... Implications of China's Growing Influence in Global Pha... FDA Issues Warning to Tianjin Darentang for Manufacturi... Shanghai Pharma Considers API Partnerships with Indian ... Aurobindo Challenges China in the Global Penicillin G M...

Early Clinical Data from China Show Promise for In Vivo... Everest Medicines Announces NMPA Full Approval of NEFEC... Roche's Columvi Wins Expanded Approval in China for 2L+... CStone Unveils Promising Preclinical Data for Trispecif... Kintor Reports Superior Hair Regrowth Results for KX-82...

BioAtla and BeiGene Revise Global Deal for Novel Condit... Pfizer to Absorb Mylan, Creating Global Generic Powerho... PhRMA Calls for Trade Deals That Force Countries to Pay... IQVIA: Global Pharma to Grow Slower in the Next Five Ye... Pfizer and GSK Announce JV to Create a Global Consumer ...

Recent Executive Moves Recent Executive Moves Recent Executive Moves Recent Executive Moves Recent Executive Moves

China Introduces Plan for Pudong New Area's Pilot Compr... Upcoming Event: 2023 Pharma CI USA Conference & Exhibit... Upcoming Event: 15th Annual Pharma Market Research Conf... Upcoming Event: 6th International Conference on Emergin... Upcoming Event: PHARM Connect Congress

Pharma China is the most influential English media and source of business intelligence covering the Chinese pharmaceutical and biopharmaceutical sector...

WiCON has been helping international healthcare companies succeed in China and other Asian markets since 1991. We advise our clients on every stage of their China and Asian business. We worked with clients in many regions of the world...

2023 Order Form + Product Descripti... WiCON Publishes the China Pharmaceu... WiCON Publishes the China Pharmaceu... WiCON Publishes the China Pharmaceu... WiCON Publishes the China Pharmaceu...